Decision Variables – Guideline Analytics

Shows truncated result set for single terms of decision variable when submitted to the UMLS. See filtered version in another tab.
Guideline Title	Conditional	Decision Variable	UMLS
Heart Failure 2017 ACC/AHA/HFSA	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	patients presenting with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	patients with idiopathic dilated cardiomyopathy	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Dilated fundus evaluation performed within 12 months prior to cataract surgery (E
Heart Failure 2017 ACC/AHA/HFSA	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	at each patient encounter	{"Endoscope Sheaths":"C0490966","Federally qualified health center (fqhc) visit, mental health, new patient; a medically-necessary, face-to-face mental health encounter (one-on-one) between a new patient and a fqhc practitioner during which time one
Heart Failure 2017 ACC/AHA/HFSA	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	ambulatory or hospitalized patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","ALCOHOL AND\/O
Heart Failure 2017 ACC/AHA/HFSA	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Initial laboratory evaluation of patients presenting with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Dmepos item, initial claim, purchase or first month rental":"C0497638","Level 1 o
Heart Failure 2017 ACC/AHA/HFSA	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	Serial monitoring indicated	{"Incision of brain tissue with seizure monitoring":"C3515163","Removal of an implantable, patient-activated cardiac event recorder":"C0812482","X-ray of upper gastrointestinal tract with small intestine, with multiple serial films":"C3866365","Presc
Heart Failure 2017 ACC/AHA/HFSA	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	patients presenting with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	selected patients who present with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Chlamydia, gonorrhea and syphilis screening results documented (report when resul
Heart Failure 2017 ACC/AHA/HFSA	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	patients presenting with HF in whom there is a clinical suspicion of rheumatological diseases, amyloidosis, or pheochromocytoma	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Investigational clinical service provided in a clinical research study that is in
Heart Failure 2017 ACC/AHA/HFSA	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	patients at risk of developing HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Prenatal care,
Heart Failure 2017 ACC/AHA/HFSA	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	patients presenting with dyspnea	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	chronic HF	{"Open reduction of chronic dislocation of elbow":"C3518824","Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute
Heart Failure 2017 ACC/AHA/HFSA	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission to the hospital	{"Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site\/side\/patient\/procedure\/implant event; or a hospital transfer or hospital admission upon discharge from the
Heart Failure 2017 ACC/AHA/HFSA	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	During a HF hospitalization	{"Patient in hospice at any time during the measurement period":"C4542719","Pathology examination of tissue during surgery":"C3516658","Her2-targeted therapies administered during the initial course of treatment":"C4316131","Partial hospitalization s
Heart Failure 2017 ACC/AHA/HFSA	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	patients with chronic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	Patients with suspected or new-onset HF,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Heart Failure 2017 ACC/AHA/HFSA	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	patients presenting with acute decompensated HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	initial evaluation of patients presenting with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Dmepos item, initial claim, purchase or first month rental":"C0497638","Level 1 o
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	who have had a significant change in clinical status	{"Patient documented to have experienced a fall within asc":"C3534791","Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history;
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	who have experienced or recovered from a clinical event	{"Patient documented to have experienced a fall within asc":"C3534791","Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site\/side\/patient\/procedure\/implant event
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	who have received treatment, including GDMT, that might have had a significant effect on cardiac function	{"Patient documented to have experienced a fall within asc":"C3534791","Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history;
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	who may be candidates for device therapy	{"Patient is not on a statin therapy":"C4316156","Flutter device":"C0994172","Speech therapy, in the home, per diem":"C0812852","Narrowing device, wheelchair":"C0498549","Insertion of radiation therapy devices in vagina for radiation therapy":"C35148
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	patients presenting with de novo HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	who have known CAD	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have verification and documentation of sudden or rapidly progressive hearing loss":"C2729209","APC (adenomatous polyposis coli) (eg, familial adenomatosis polypo
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	no angina	{"Severity of angina assessed by level of activity (CAD)":"C3248256","Angina present (CAD)":"C3248257","Angina absent (CAD)":"C3248525"}
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	unless the patient is not eligible for revascularization of any kind.	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, gen
Heart Failure 2017 ACC/AHA/HFSA	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	select situations when planning revascularization in HF patients with CAD.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Rental (use th
Heart Failure 2017 ACC/AHA/HFSA	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	echocardiography is inadequate	{"Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exe
Heart Failure 2017 ACC/AHA/HFSA	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	assessing myocardial infiltrative processes	{"Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)":"C
Heart Failure 2017 ACC/AHA/HFSA	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	assessing scar burden	{"Release of nasal scar tissue":"C3513207","Revision of tracheostomy scar":"C0189437","Removal of scar tissue to release tendon of palm and finger":"C3512717","Release of scar tissue and repair of rectum":"C3514252","Release of scar tissue from conju
Heart Failure 2017 ACC/AHA/HFSA	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	absence of clinical status change	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Removal of suture around skin surface tube with change of bladder tube":"C3514604","Dilated macular or fundus exam performed, including documentation of the presence
Heart Failure 2017 ACC/AHA/HFSA	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	absence of treatment interventions	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Anesthesia for electroconvulsive therapy":"C0198856","Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema a
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	patients who have respiratory distress	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	patients with clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Pulmonary perfusion imaging":"C3525539","At least 60 percent but less than 80 percent impaired, limited or restrict
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	carefully selected patients with acute HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","ALCOHOL AND\/O
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	who have persistent symptoms despite empiric adjustment of standard therapies,	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have verification and documentation of sudden or rapidly progressive hearing loss":"C2729209","Powered air overlay for mattress, standard mattress length and wid
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain	{"Joint fluid diagnostic test":"C3516358","Vascular occlusion procedure":"C4281779","Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for pr
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy;	{"Dmepos item, initial claim, purchase or first month rental":"C0497638","Lipoprotein-associated phospholipase A2 assay":"C1809511","Most recent systolic blood pressure < 140 mmhg":"C2729230","Test for detecting genes associated with blood related ca
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	Whose renal function is worsening with therapy;	{"Assessment of blood clotting function":"C3516398","Lung function response to low oxygen":"C3517140","Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified h
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	Who require parenteral vasoactive agents; or	{"Parenteral nutrition infusion pump, portable":"C0498007","MUROMONAB-CD3, PARENTERAL, 5 MG ADMINISTERED":"C0520150","Manipulation of temporomandibular joint(s) (TMJ), therapeutic, requiring an anesthesia service (ie, general or monitored anesthesia
Heart Failure 2017 ACC/AHA/HFSA	Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation.	Who may need consideration for mechanical circulatory support (MCS) or transplantation.	{"Advanced life support, level 2 (als 2)":"C0918298","Cord blood harvesting for transplantation, allogeneic":"C0919176","Moisture exchanger, disposable, for use with invasive mechanical ventilation":"C0694921","Mechanical chest wall oscillation to fa
Heart Failure 2017 ACC/AHA/HFSA	When ischemia may be contributing to Heart Failure, coronary arteriography is reasonable for patients eligible for revascularization.	ischemia may be contributing to HF	{"serum albumin ischemia modified lab procedure":"C1504155","Arterial embolization for organ ischemia, with imaging guidance":"C3867986","Measurement of ischemia modified albumin":"C3525690","Arterial occlusion for organ ischemia, with imaging guidan
Heart Failure 2017 ACC/AHA/HFSA	When ischemia may be contributing to Heart Failure, coronary arteriography is reasonable for patients eligible for revascularization.	for patients eligible for revascularization.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Clinician documented that patient was not an eligible candidate for footwear eval
Heart Failure 2017 ACC/AHA/HFSA	Endomyocardial biopsy can be useful in patients presenting with Heart Failure when a specific diagnosis is suspected that would influence therapy.	patients presenting with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Level 1 outpatient visit for evaluation and management of established patient wit
Heart Failure 2017 ACC/AHA/HFSA	Endomyocardial biopsy can be useful in patients presenting with Heart Failure when a specific diagnosis is suspected that would influence therapy.	when a specific diagnosis is suspected that would influence therapy	{"Patients with a diagnosis or past history of total colectomy or colorectal cancer":"C4316221","Examination of genital and anal region of child using an endoscope, suspected trauma":"C3704131","Patient is not on a statin therapy":"C4316156","Rental
Heart Failure 2017 ACC/AHA/HFSA	Routine use of invasive hemodynamic monitoring is NOT recommended in normotensive patients with acute decompensated Heart Failure and congestion with symptomatic response to diuretics and vasodilators.	normotensive patients with acute decompensated HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","ALCOHOL AND\/O
Heart Failure 2017 ACC/AHA/HFSA	Routine use of invasive hemodynamic monitoring is NOT recommended in normotensive patients with acute decompensated Heart Failure and congestion with symptomatic response to diuretics and vasodilators.	congestion with symptomatic response to diuretics and vasodilators	{"All lower extremity prosthesis, multi-axial ankle, dynamic response foot, one piece system":"C0499983","Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon":"C0973412","Lung function response to low oxygen":"C35
Heart Failure 2017 ACC/AHA/HFSA	Endomyocardial biopsy should NOT be performed in the routine evaluation of patients with Heart Failure.	routine evaluation of patients with HF	{"Routine electrocardiogram (EKG) with tracing using at least 12 leads":"C3516975","Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203",
Heart Failure 2017 ACC/AHA/HFSA	Hypertension and lipid disorders should be controlled in accordance with contemporary guidelines to lower the risk of Heart Failure.	lowering the risk of HF	{"One high-risk medication not ordered":"C3871285","Initiation of lowering head or total body temperature in neonate":"C3865483","Prenatal care, at risk enhanced service; care coordination":"C0993932","Specialized mental health programs for high-risk
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	obesity	{"Revision or replacement of neurostimulator electrodes for vagus nerve blocking therapy for obesity using an endoscope":"C3704178","Gastric restrictive procedure, without gastric bypass, for morbid obesity":"C3701757","Vagus nerve blocking therapy (
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	diabetes mellitus	{"Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day":"C4051821","Diabetes outpatient self-manag
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	tobacco use	{"Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	known cardiotoxic agents	{"Application of chemical agents activated by ultraviolet light to skin":"C3517288","APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants":"C3511543","Application of chemi
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	patients with a recent or remote history of MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients with a diagnosis or past history of total colectomy or colorectal cancer
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	acute coronary syndrome	{"Chromosome analysis for breakage syndrome":"C2121076","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angiop
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	reduced EF	{"PLASMA, CRYOPRECIPITATE REDUCED, EACH UNIT ADMINISTERED":"C0919124","Platelets, pheresis, pathogen-reduced, each unit":"C4521664","Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit":"C1314478","Intraocular pressure (IOP) r
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	patients with a recent or remote history of MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients with a diagnosis or past history of total colectomy or colorectal cancer
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	acute coronary syndrome	{"Chromosome analysis for breakage syndrome":"C2121076","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angiop
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	reduced EF	{"PLASMA, CRYOPRECIPITATE REDUCED, EACH UNIT ADMINISTERED":"C0919124","Platelets, pheresis, pathogen-reduced, each unit":"C4521664","Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit":"C1314478","Intraocular pressure (IOP) r
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	patients intolerant of ACE inhibitors	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Plasminogen antigen assay":"C0200467","Patients prescribed opiates for longer tha
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	patients with a recent or remote history of MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients with a diagnosis or past history of total colectomy or colorectal cancer
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	acute coronary syndrome	{"Chromosome analysis for breakage syndrome":"C2121076","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angiop
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	reduced EF	{"PLASMA, CRYOPRECIPITATE REDUCED, EACH UNIT ADMINISTERED":"C0919124","Platelets, pheresis, pathogen-reduced, each unit":"C4521664","Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit":"C1314478","Intraocular pressure (IOP) r
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome, statins should be used to prevent symptomatic Heart Failure and cardiovascular events.	patients with a recent or remote history of MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients with a diagnosis or past history of total colectomy or colorectal cancer
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome, statins should be used to prevent symptomatic Heart Failure and cardiovascular events.	acute coronary syndrome	{"Chromosome analysis for breakage syndrome":"C2121076","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angiop
Heart Failure 2017 ACC/AHA/HFSA	In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic Heart Failure.	patients with structural cardiac abnormalities, including LV hypertrophy	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Metal-on-metal
Heart Failure 2017 ACC/AHA/HFSA	In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic Heart Failure.	the absence of a history of MI or ACS	{"Documentation of patient survival and absence of stroke following cea":"C3710365","History of injection drug use":"C3871344","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors should be used in all patients with a reduced EF to prevent symptomatic Heart Failure, even if they do not have a history of MI.	patients with a reduced EF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","PLASMA, CRYOPRECIPITATE REDUCED, EACH UNIT ADMINISTERED":"C0919124","Platelets, p
Heart Failure 2017 ACC/AHA/HFSA	Beta blockers should be used in all patients with a reduced EF to prevent symptomatic Heart Failure, even if they do not have a history of MI.	patients with a reduced EF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","PLASMA, CRYOPRECIPITATE REDUCED, EACH UNIT ADMINISTERED":"C0919124","Platelets, p
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Documentation
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	have an LVEF of ?30%,	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	are on appropriate medical therapy	{"Patient is not on a statin therapy":"C4316156","ALCOHOL AND\/OR DRUG SERVICES; MEDICAL\/SOMATIC (MEDICAL INTERVENTION IN AMBULATORY SETTING)":"C0919052","Speech therapy, in the home, per diem":"C0812852","Insertion of radiation therapy devices in v
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	have a reasonable expectation of survival with a good functional status for >1 year.	{"Patient documented to have experienced a fall within asc":"C3534791","Documentation of patient survival and absence of stroke following cea":"C3710365","Storage (per year); embryo(s)":"C1314113","Survival of motor neuron 1, telomeric (SMN1) gene an
Heart Failure 2017 ACC/AHA/HFSA	Nondihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of Heart Failure after MI.	asymptomatic patients with low LVEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g.
Heart Failure 2017 ACC/AHA/HFSA	Nondihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of Heart Failure after MI.	no symptoms of HF after MI.	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Anginal symptoms and level of activity assessed (CAD)":"C1314138","Thoracotomy; for postoperative complications":"C0189510","CT scan of lower spine before and after contrast
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure should receive specific education to facilitate Heart Failure self-care.	Patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Sodium restriction is reasonable for patients with symptomatic Heart Failure to reduce congestive symptoms.	patients with symptomatic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Exercise training (or regular physical activity) is recommended as safe and effective for patients with Heart Failure who are able to participate to improve functional status.	patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Exercise training (or regular physical activity) is recommended as safe and effective for patients with Heart Failure who are able to participate to improve functional status.	who are able to participate to improve functional status	{"Repair to improve congenital blood flow defect from single lower heart chamber":"C3513538","Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitorin
Heart Failure 2017 ACC/AHA/HFSA	Cardiac rehabilitation can be useful in clinically stable patients with Heart Failure to improve functional capacity, exercise duration, health-related quality of life (HRQOL), and mortality.	clinically stable patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Drug test(s),
Heart Failure 2017 ACC/AHA/HFSA	Measures listed as Class I recommendations for patients in stages A and B are recommended where appropriate for patients in stage C. (I-A, I-B, and I-C as appropriate)	patients in stage C	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","1-stage":"C386
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	Stage C patient with HFrEF	{"Patient is not on a statin therapy":"C4316156","1-stage":"C3867743","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Lifestyle modification program for management of coronary arte
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	NYHA class I-IV	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I)	patient is NYHA class II–IV	{"Patient is not on a statin therapy":"C4316156","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Antibody detection for HLA class II":"C3525863","Patient was not admitted to hospic
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I)	provided est. CrCl >30 mL/min	{"Services provided on an emergency basis in the office":"C3517342","ORBITAL PROSTHESIS, PROVIDED BY A NON-PHYSICIAN":"C0919102","Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appr
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I)	K+ <5.0 mEq/L	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III Heart Failure Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril then Discontinue ACEI or ARB; initiate ARNI	NYHA class II–III HF	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III Heart Failure Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril then Discontinue ACEI or ARB; initiate ARNI	Adequate blood pressure on angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker	{"Leucine aminopeptidase measurement":"C0202118","streptokinase antibody assay (lab test)":"C0200486","Cystatin C (enzyme inhibitor) level":"C3516331","Alanine aminotransferase measurement":"C0201836","Clotting inhibitors or anticoagulants; antithrom
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III Heart Failure Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril then Discontinue ACEI or ARB; initiate ARNI	No contraindication to angiotensin receptor-blocker or sacubitril	{"Angiotensin II Assay":"C0373546","Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy not prescribed, reason not given":"C1971313","Clinician documented that patient was not an eligible candidate for angioten
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	NYHA class III–IV	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	in black patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	NYHA class II–III	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	left ventricular ejection fraction ?35%	{"Left foot, great toe":"C0497698","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)":"C1740749","Delivery of single fraction of multi-fraction course of ste
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	(caveat: >1 y survival, >40 d post MI)	{"Dilation and curettage of uterus after delivery":"C0195637","Other scoliosis procedure, post-operative body jacket":"C0499480","Postmortem period":"C0580205","Post-coital direct, qualitative examinations of vaginal or cervical mucous":"C0500275","P
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	NYHA class II–IV	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	left ventricular ejection fraction ?35%	{"Left foot, great toe":"C0497698","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)":"C1740749","Delivery of single fraction of multi-fraction course of ste
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	normal sinus rhythm and QRS ?150 ms with left bundle-branch block pattern	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Left ventricular ejection fraction (lvef) < 40%":"C3248440","This code is for the onsite acute care treatment of a nursing facility resident with fluid or electrolyte diso
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	NYHA class II–III,	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	normal sinus rhythm,	{"Hydration status assessed (normal\/mildly dehydrated\/severely dehydrated) (CAP)":"C1738527","INFUSION, NORMAL SALINE SOLUTION , 1000 CC ADMINISTERED":"C0499045","Anesthesia for soft tissue biopsy on nose and sinus":"C2065618","Open treatment of fr
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	heart rate ?70 bpm on maximally tolerated dose beta blocker	{"Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Anesthesia for heart\/lung transplant":"C0198934","Transplantation of donor heart":"C3513602","Beta-blocker therapy not prescribed":"C1971293","B
Heart Failure 2017 ACC/AHA/HFSA	patients are Stage D refractory NYHA class III-IV consider additional therapy of palliative care (COR I) or transplant (COR I) or left ventricular assist device (COR IIa) or Investigational studies	patients are Stage D refractory NYHA class III-IV	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","1-stage":"C386
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF with fluid retention	patients with HFrEF with fluid retention	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Joint fluid diagnostic test":"C3516358","Patients prescribed opiates for longer t
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended for all patients with Heart FailurerEF	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF who are ACE inhibitor–intolerant	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF who are ACE inhibitor–intolerant	who are ACE inhibitor–intolerant	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	patient with HFrEF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	first-line therapy	{"Patient is not on a statin therapy":"C4316156","Iv chelation therapy (chemical endarterectomy)":"C0500226","Administration of radiation therapy":"C0886115","Speech therapy, in the home, per diem":"C0812852","Amoxicillin, with or without clavulanate
Heart Failure 2017 ACC/AHA/HFSA	Addition of an ARB may be considered in persistently symptomatic patients with Heart FailurerEF on GDMT	persistently symptomatic patients with HFrEF on GDMT	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	stable patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Drug test(s),
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV Heart Failure who have LVEF ?35%	patients with NYHA class II–IV HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Antibody detec
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV Heart Failure who have LVEF ?35%	who have LVEF ?35%	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	patients following an acute MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Documentation of patient survival and absence of stroke following cea":"C3710365"
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	who have LVEF ?40%	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	who develop symptoms of HF	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Anginal symptoms and level of activity assessed (CAD)":"C1314138","ALCOHOL AND\/OR DRUG PREVENTION PROCESS SERVICE, COMMUNITY-BASED (DELIVERY OF SERVICES TO DEVELOP SKILLS O
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	who have a history of diabetes mellitus	{"Patient documented to have experienced a fall within asc":"C3534791","History of injection drug use":"C3871344","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Pa
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	serum creatinine is >2.5 mg/dL in men	{"Serum potassium measurement":"C0302353","Serum proteins measurement":"C0740182","Creatinine clearance measurement to test for kidney function":"C3516330","Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative":"C0373529
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	>2.0 mg/dL in women	{"Women who had an endometrial ablation procedure during the year prior to the index date (exclusive of the index date)":"C4316136","Counseling for women of childbearing potential with epilepsy (EPI)":"C2724386","NO RESULTS":"NONE","Women who had a b
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	or estimated glomerular filtration rate <30 mL/min/1.73 m2	{"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	and/or potassium >5.0 mEq/L.	{"Serum potassium measurement":"C0302353","Tissue examination by potassium hydroxide slide of sample from hair for ectoparasite ova":"C3525994","5% dextrose with potassium chloride, 1000 ml":"C0919194","Tissue examination by potassium hydroxide slide
Heart Failure 2017 ACC/AHA/HFSA	The combination of hydralazine and isosorbide dinitrate is recommended for African Americans with NYHA class III–IV Heart FailurerEF on GDMT	African Americans with NYHA class III–IV HFrEF on GDMT	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful in patients with Heart FailurerEF who cannot be given ACE inhibitors or ARBs	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful in patients with Heart FailurerEF who cannot be given ACE inhibitors or ARBs	who cannot be given ACE inhibitors or ARBs	{"Plasminogen antigen assay":"C0200467","Aspirin or another antiplatelet therapy not used, reason not given":"C2729239","Positive airway pressure therapy not prescribed, reason not given":"C3248584","Beta-blocker therapy not prescribed, reason not gi
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	Patients with chronic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	with permanent/persistent/paroxysmal AF	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	an additional risk factor for cardioembolic stroke	{"Observational behavioral follow-up assessment additional 30 minutes":"C3865459","Documentation of patient survival and absence of stroke following cea":"C3710365","Nuclear medicine additional studies for thyroid cancer":"C3516086","Prenatal care, a
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	absence of contraindications to anticoagulation	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy":"C1971243","Fistu
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin. (	permanent/persistent/paroxysmal AF	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation). (	patients with chronic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation). (	who have permanent/persistent/paroxysmal AF	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Patient does not have verification and documentation of sudden or rapidly progressive hearing loss":"C2729209",
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation). (	are without an additional risk factor for cardioembolic stroke	{"Observational behavioral follow-up assessment additional 30 minutes":"C3865459","Documentation of patient survival and absence of stroke following cea":"C3710365","MRI of bilateral breasts without contrast":"C0993826","Magnetic resonance imaging of
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation). (	(in the absence of contraindications to anticoagulation).	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy":"C1971243","Fistu
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	patients with chronic HFrEF without AF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	a prior thromboembolic event	{"Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site\/side\/patient\/procedure\/implant event; or a hospital transfer or hospital admission upon discharge from the
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	a cardioembolic source	{"Brachytherapy source, stranded, iodine-125, per source":"C1971548","Brachytherapy source, non-stranded, cesium-131, per source":"C1971553","Insertion of radiation source applicator into eye":"C3517559","Culture, mycoplasma, any source":"C0374008","
Heart Failure 2017 ACC/AHA/HFSA	Statins are NOT beneficial as adjunctive therapy when prescribed solely for Heart Failure	prescribed solely for HF	{"Antibiotic regimen prescribed":"C4067449","Systemic antimicrobials not prescribed":"C2367629","Patient not prescribed or dispensed antibiotic":"C3248453","Anticoagulant therapy prescribed at discharge (STR)":"C1964148","Beta-blocker therapy not pre
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	HFrEF patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	HFpEF patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Nutritional supplements as treatment for Heart Failure are NOT recommended in patients with current or prior symptoms of Heart FailurerEF. (	patients with current or prior symptoms of HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	patient with HFrEF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	Drugs known to adversely affect the clinical status of patients with current or prior symptoms of Heart FailurerEF are potentially harmful and should be avoided or withdrawn whenever possible (eg, most antiarrhythmic drugs, most calcium channel–blocking drugs [except amlodipine], nonsteroidal anti-inflammatory drugs, or thiazolidinediones).	patients with current or prior symptoms of HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	patient with HFrEF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors OR ARBs in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic Heart FailurerEF to reduce morbidity and mortality.	patients with chronic HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	The clinical strategy of inhibition of the renin-angiotensin system with ARNI in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic Heart FailurerEF to reduce morbidity and mortality.	patients with chronic HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	The use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic Heart FailurerEF to reduce morbidity and mortality.	patients with prior or current symptoms of chronic HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	The use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic Heart FailurerEF who are intolerant to ACE inhibitors because of cough or angioedema.	patients with prior or current symptoms of chronic HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	The use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic Heart FailurerEF who are intolerant to ACE inhibitors because of cough or angioedema.	who are intolerant to ACE inhibitors because of cough or angioedema	{"Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio for injection into muscle":"C3703982","Spirometry test results demonstrate FEV1\/FVC less than 70% with COPD symptoms (eg, dyspnea, cough\/sputum,
Heart Failure 2017 ACC/AHA/HFSA	In patients with chronic symptomatic Heart FailurerEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality.	In patients with chronic symptomatic HFrEF NYHA class II or III	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	In patients with chronic symptomatic Heart FailurerEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality.	who tolerate an ACE inhibitor or ARB	{"Plasminogen antigen assay":"C0200467","Injection, c-1 esterase inhibitor (human), haegarda, 10 units":"C4542685","Injection, c-1 esterase inhibitor (human), berinert, 10 units":"C2959233","Angiotensin converting enzyme (ace) inhibitor or angiotensi
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered to patients with a history of angioedema.	patients with a history of angioedema	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","History of injection drug use":"C3871344","Patients with a diagnosis or past hist
Heart Failure 2017 ACC/AHA/HFSA	Ivabradine can be beneficial to reduce Heart Failure hospitalization for patients with symptomatic (NYHA class II-III) stable chronic Heart FailurerEF (LVEF ?35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ?70 bpm at rest.	patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF ?35%)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Ivabradine can be beneficial to reduce Heart Failure hospitalization for patients with symptomatic (NYHA class II-III) stable chronic Heart FailurerEF (LVEF ?35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ?70 bpm at rest.	who are receiving GDEM, including a beta blocker at maximum tolerated dose,	{"Patient receiving antiviral treatment for Hepatitis C (HEP-C)":"C1971487","Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Metal-on-metal total hip resurfacing, including acetabular and femoral
Heart Failure 2017 ACC/AHA/HFSA	Ivabradine can be beneficial to reduce Heart Failure hospitalization for patients with symptomatic (NYHA class II-III) stable chronic Heart FailurerEF (LVEF ?35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ?70 bpm at rest.	who are in sinus rhythm with a heart rate of ?70 bpm at rest.	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Anesthesia for heart\/lung transplant":"C0198934","Transplantation of donor heart":"C3513602","Ultrasound examination of the heart performed during rest, exercise, and\/or
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	who have evidence of fluid retention	{"Patient documented to have experienced a fall within asc":"C3534791","Joint fluid diagnostic test":"C3516358","Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit":"C3
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	not contraindicated	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended in patients with Heart FailurerEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality.	patients with HFrEF and current or prior symptoms,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended in patients with Heart FailurerEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality.	not contraindicated	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF with current or prior symptoms who are ACE inhibitor–intolerant, unless contraindicated, to reduce morbidity and mortality.	patients with HFrEF with current or prior symptoms	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF with current or prior symptoms who are ACE inhibitor–intolerant, unless contraindicated, to reduce morbidity and mortality.	who are ACE inhibitor–intolerant	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF with current or prior symptoms who are ACE inhibitor–intolerant, unless contraindicated, to reduce morbidity and mortality.	not contraindicated	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable to reduce morbidity and mortality as alternatives to ACE inhibitors as first-line therapy for patients with Heart FailurerEF, especially for patients already taking ARBs for other indications, unless contraindicated.	first-line therapy for patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient is not on a statin therapy":"C4316156","Patients prescribed opiates for l
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable to reduce morbidity and mortality as alternatives to ACE inhibitors as first-line therapy for patients with Heart FailurerEF, especially for patients already taking ARBs for other indications, unless contraindicated.	patients already taking ARBs for other indications	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient is currently on a daily aspirin or other antiplatelet":"C4316160","Patien
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable to reduce morbidity and mortality as alternatives to ACE inhibitors as first-line therapy for patients with Heart FailurerEF, especially for patients already taking ARBs for other indications, unless contraindicated.	not contraindicated	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Addition of an ARB may be considered in persistently symptomatic patients with Heart FailurerEF who are already being treated with an ACE inhibitor and a beta blocker in whom an aldosterone antagonist is not indicated or tolerated.	persistently symptomatic patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Addition of an ARB may be considered in persistently symptomatic patients with Heart FailurerEF who are already being treated with an ACE inhibitor and a beta blocker in whom an aldosterone antagonist is not indicated or tolerated.	who are already being treated with an ACE inhibitor and a beta blocker i	{"Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Examination of kidney using an endoscopy which is inserted through an already created kidney opening":"C3703534","Patient has been treated with a
Heart Failure 2017 ACC/AHA/HFSA	Addition of an ARB may be considered in persistently symptomatic patients with Heart FailurerEF who are already being treated with an ACE inhibitor and a beta blocker in whom an aldosterone antagonist is not indicated or tolerated.	an aldosterone antagonist is not indicated or tolerated.	{"Appendectomy; when done for indicated purpose at time of other major procedure (not as separate procedure) (List separately in addition to code for primary procedure)":"C0372105","Continuous (12-months) therapy with proton pump inhibitor (PPI) or h
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality (ie, bisoprolol, carvedilol, and sustained-release metoprolol succinate) is recommended for all patients with current or prior symptoms of Heart FailurerEF, unless contraindicated, to reduce morbidity and mortality.	for all patients with current or prior symptoms of HFrEF,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality (ie, bisoprolol, carvedilol, and sustained-release metoprolol succinate) is recommended for all patients with current or prior symptoms of Heart FailurerEF, unless contraindicated, to reduce morbidity and mortality.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	patients with NYHA class II–IV	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Antibody detec
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	and who have LVEF of ?35%	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists.	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Elevated blood pressure plan of care documented (CKD)":"C1971414","Antibody detection for HLA class II":"C3525863",
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2)	{"Documented history of renal failure or baseline serum creatinine = 4.0 mg\/dl; renal transplant recipients are not considered to have preoperative renal failure, unless, since transplantation the cr has been or is 4.0 or higher":"C4316215","Stimula
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	and potassium levels should be <5.0 mEq/L.	{"5% dextrose with potassium chloride, 1000 ml":"C0919194","Tissue examination by potassium hydroxide slide of sample from skin for ectoparasite ova":"C3526000","Tissue examination by potassium hydroxide slide of sample from skin for fungus":"C352600
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	following an acute MI in patients	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Incision and drainage of vaginal blood accumulation following delivery":"C3514876","Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OT
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	who have LVEF of ?40%	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	who develop symptoms of HF	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Anginal symptoms and level of activity assessed (CAD)":"C1314138","ALCOHOL AND\/OR DRUG PREVENTION PROCESS SERVICE, COMMUNITY-BASED (DELIVERY OF SERVICES TO DEVELOP SKILLS O
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	or who have a history of diabetes mellitus	{"Patient documented to have experienced a fall within asc":"C3534791","History of injection drug use":"C3871344","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Pa
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists are recommended to reduce morbidity and mortality following an acute MI in patients who have LVEF of ?40% who develop symptoms of Heart Failure or who have a history of diabetes mellitus, unless contraindicated.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	serum creatinine is >2.5 mg/dL in men	{"Serum potassium measurement":"C0302353","Serum proteins measurement":"C0740182","Creatinine clearance measurement to test for kidney function":"C3516330","Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative":"C0373529
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	>2.0 mg/dL in women	{"Women who had an endometrial ablation procedure during the year prior to the index date (exclusive of the index date)":"C4316136","Counseling for women of childbearing potential with epilepsy (EPI)":"C2724386","NO RESULTS":"NONE","Women who had a b
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	estimated glomerular filtration rate <30 mL/min/1.73 m2	{"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	potassium >5.0 mEq/L	{"Serum potassium measurement":"C0302353","Tissue examination by potassium hydroxide slide of sample from hair for ectoparasite ova":"C3525994","5% dextrose with potassium chloride, 1000 ml":"C0919194","Tissue examination by potassium hydroxide slide
Heart Failure 2017 ACC/AHA/HFSA	The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients selfdescribed as African Americans with NYHA class III–IV Heart FailurerEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated.	patients self-described as African Americans with NYHA class III–IV HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Antibody detec
Heart Failure 2017 ACC/AHA/HFSA	The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients selfdescribed as African Americans with NYHA class III–IV Heart FailurerEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated.	receiving optimal therapy with ACE inhibitors and beta blockers	{"Patient receiving antiviral treatment for Hepatitis C (HEP-C)":"C1971487","Patient is not on a statin therapy":"C4316156","Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Speech therapy, in the
Heart Failure 2017 ACC/AHA/HFSA	The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients selfdescribed as African Americans with NYHA class III–IV Heart FailurerEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful to reduce morbidity or mortality in patients with current or prior symptomatic Heart FailurerEF who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency, unless contraindicated.	patients with current or prior symptomatic HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful to reduce morbidity or mortality in patients with current or prior symptomatic Heart FailurerEF who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency, unless contraindicated.	who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency,	{"Cystatin C (enzyme inhibitor) level":"C3516331","Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's status survey near discharge, not appropriate":"C2959185","Clotting inhibi
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful to reduce morbidity or mortality in patients with current or prior symptomatic Heart FailurerEF who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency, unless contraindicated.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	unless contraindicated	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	Patients with chronic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	with permanent/persistent/paroxysmal AF	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age)	{"Observational behavioral follow-up assessment additional 30 minutes":"C3865459","Documentation of patient survival and absence of stroke following cea":"C3710365","Magnetic resonance imaging of fetus, each additional pregnancy":"C4051978","Cast sup
Heart Failure 2017 ACC/AHA/HFSA	Patients with chronic Heart Failure with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ?75 years of age) should receive chronic anticoagulant therapy (in the absence of contraindications to anticoagulation).	(in the absence of contraindications to anticoagulation).	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy":"C1971243","Fistu
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	on the basis of risk factors	{"Services provided on an emergency basis in the office":"C3517342","Prenatal care, at risk enhanced service; care coordination":"C0993932","Specialized mental health programs for high-risk populations":"C1144858","Coordinated care fee, risk adjusted
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	cost	{"Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and childr
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	tolerability	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	patient preference	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	potential for drug interactions	{"History of injection drug use":"C3871344","Lower extremity prosthesis functional level 2 - has the ability or potential for ambulation with the ability to traverse low level environmental barriers such as curbs, stairs or uneven surfaces. typical o
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin	{"Training for home international normalized ratio (INR) monitoring of blood thinner therapy":"C4523610","Patient is currently on a daily aspirin or other antiplatelet":"C4316160","Patient is not on a statin therapy":"C4316156","Patient\/caregiver tr
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation).	patients with chronic HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation).	who have permanent/persistent/paroxysmal AF	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Patient does not have verification and documentation of sudden or rapidly progressive hearing loss":"C2729209",
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation).	but are without an additional risk factor for cardioembolic stroke	{"Observational behavioral follow-up assessment additional 30 minutes":"C3865459","Documentation of patient survival and absence of stroke following cea":"C3710365","MRI of bilateral breasts without contrast":"C0993826","Magnetic resonance imaging of
Heart Failure 2017 ACC/AHA/HFSA	Chronic anticoagulation is reasonable for patients with chronic Heart Failure who have permanent/persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke (in the absence of contraindications to anticoagulation).	in the absence of contraindications to anticoagulation	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy":"C1971243","Fistu
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	patients with chronic HFrEF without AF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Open reduction of chronic dislocation of elbow":"C3518824","Patients prescribed o
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	a prior thromboembolic event	{"Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site\/side\/patient\/procedure\/implant event; or a hospital transfer or hospital admission upon discharge from the
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	a cardioembolic source	{"Brachytherapy source, stranded, iodine-125, per source":"C1971548","Brachytherapy source, non-stranded, cesium-131, per source":"C1971553","Insertion of radiation source applicator into eye":"C3517559","Culture, mycoplasma, any source":"C0374008","
Heart Failure 2017 ACC/AHA/HFSA	Statins are NOT beneficial as adjunctive therapy when prescribed solely for the diagnosis of Heart Failure in the absence of other indications for their use.	Statins are prescribed solely for the diagnosis of HF in the absence of other indications for their use	{"Patients with a diagnosis or past history of total colectomy or colorectal cancer":"C4316221","Documentation of patient survival and absence of stroke following cea":"C3710365","Patient is currently on a daily aspirin or other antiplatelet":"C43161
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 polyunsaturated fatty acid (PUFA) supplementation is reasonable to use as adjunctive therapy in patients with NYHA class II–IV symptoms and Heart FailurerEF or Heart FailurepEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations.	patients with NYHA class II–IV symptoms	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Patien
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 polyunsaturated fatty acid (PUFA) supplementation is reasonable to use as adjunctive therapy in patients with NYHA class II–IV symptoms and Heart FailurerEF or Heart FailurepEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations.	HFrEF	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 polyunsaturated fatty acid (PUFA) supplementation is reasonable to use as adjunctive therapy in patients with NYHA class II–IV symptoms and Heart FailurerEF or Heart FailurepEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations.	or HFpEF	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 polyunsaturated fatty acid (PUFA) supplementation is reasonable to use as adjunctive therapy in patients with NYHA class II–IV symptoms and Heart FailurerEF or Heart FailurepEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations.	unless contraindicated,	{"Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm":"C0370395","Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck
Heart Failure 2017 ACC/AHA/HFSA	Nutritional supplements as treatment for Heart Failure are NOT recommended in patients with current or prior symptoms of Heart FailurerEF.	patients with current or prior symptoms of HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended for patients with current or prior symptoms of Heart FailurerEF.	patients with current or prior symptoms of HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Drugs known to adversely affect the clinical status of patients with current or prior symptoms of Heart FailurerEF are potentially harmful and should be avoided or withdrawn whenever possible (eg, most antiarrhythmic drugs, most calcium channel–blocking drugs [except amlodipine], nonsteroidal anti-inflammatory drugs, or thiazolidinediones).	patients with current or prior symptoms of HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Flow cytometry studies performed at time of diagnosis or prior to initiating trea
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations for stage D starting on page 34).	patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment for patients with Heart FailurerEF.	patients with HFrEF.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Systolic and diastolic blood pressure should be controlled in patients with Heart FailurepEF in accordance with published clinical practice guidelines to prevent morbidity.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Diuretics should be used for relief of symptoms due to volume overload in patients with Heart FailurepEF.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Coronary revascularization is reasonable in patient with CAD in whom symptoms (angina) or demonstrable myocardial ischemia is judged to be having an adverse effect on symptomatic Heart FailurepEF despite GDMT.	patient with CAD in whom symptoms (angina) or demonstrable myocardial ischemia is judged to be having an adverse effect on symptomatic HFpEF despite GDMT	{"Patient is not on a statin therapy":"C4316156","Documentation of patient reason(s) for not having records of negative or managed positive tb screen (e.g., patient does not return for mantoux (ppd) skin test evaluation)":"C4542762","serum albumin is
Heart Failure 2017 ACC/AHA/HFSA	Management of AF according to published clinical practice guidelines in patients with Heart FailurepEF is reasonable to improve symptomatic Heart Failure.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	patients with hypertension	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	In appropriately selected patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	with EF ?45%	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	, elevated BNP levels	{"Antipsychotics levels":"C3865519","Elevated blood pressure plan of care documented (CKD)":"C1971414","Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algo
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	or HF admission within 1 year	{"Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site\/side\/patient\/procedure\/implant event; or a hospital transfer or hospital admission upon discharge from the
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	, estimated glomerular filtration rate >30 mL/min,	{"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary
Heart Failure 2017 ACC/AHA/HFSA	In appropriately selected patients with Heart FailurepEF (with EF ?45%, elevated BNP levels or Heart Failure admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations.	creatinine <2.5 mg/dL, potassium <5.0 mEq/L),	{"Serum potassium measurement":"C0302353","Tissue examination by potassium hydroxide slide of sample from hair for ectoparasite ova":"C3525994","Creatinine clearance measurement to test for kidney function":"C3516330","5% dextrose with potassium chlo
Heart Failure 2017 ACC/AHA/HFSA	The use of ARBs might be considered to decrease hospitalizations for patients with Heart FailurepEF.	for patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with Heart FailurepEF is ineffective.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nutritional supplements is not recommended for patients with Heart FailurepEF.	patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	selected patients with nonischemic DCM	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	or ischemic heart disease ?40 days	{"Repair of wound to heart on heart-lung machine":"C3513471","Anesthesia for heart\/lung transplant":"C0198934","Unplanned hospital readmission within 30 days of principal procedure":"C3710411","Transplantation of donor heart":"C3513602","A patient w
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	post-MI	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	with LVEF of ?35%	{"Left ventricular ejection fraction (lvef) < 40%":"C3248440","Left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function":"C3248480","Left ventricular ejection fraction (LV
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	and NYHA class II or III symptoms	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","Antibiotic regimen not prescribed within 10 days after onset of symptoms":"C4067437","HLA class I typing low resolution":"C3
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	on chronic GDMT	{"Open reduction of chronic dislocation of elbow":"C3518824","Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of sudden cardiac death (SCD) to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease ?40 days post-MI with LVEF of ?35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for >1 year.a .a (I-A)	, who have a reasonable expectation of meaningful survival for >1 year	{"Patient documented to have experienced a fall within asc":"C3534791","Documentation of patient survival and absence of stroke following cea":"C3710365","Storage (per year); embryo(s)":"C1314113","Documentation of negative or managed positive tb scr
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	patients who have LVEF of 35% or less	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	left bundle-branch block with a QRS duration of 150 ms or greater	{"Left foot, great toe":"C0497698","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery stat
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	NYHA class II, III, or ambulatory class IV symptoms	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","ALCOHOL AND\/OR DRUG SERVICES; MEDICAL\/SOMATIC (MEDICAL INTERVENTION IN AMBULATORY SETTING)":"C0919052","Ambulatory continu
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	on GDMT	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have a reasonable expectation of meaningful survival for more than 1 year.	selected patients at least 40 days post-MI	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Routine electrocardiogram (EKG) with tracing using at least 12 leads":"C3516975",
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have a reasonable expectation of meaningful survival for more than 1 year.	with LVEF of 30% or less	{"Radiologic examination, teeth; partial examination, less than full mouth":"C0202776","Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less) (procedure)":"C0373388","Left ventricular ejection fraction (lvef) < 40%"
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have a reasonable expectation of meaningful survival for more than 1 year.	NYHA class I symptoms while receiving GDMT	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Patient receiving antiviral treatment for Hepatitis C (HEP-C)":"C1971487","Antibody detection for HLA class II":"C3525863","Antibiotic regimen not prescribed within 10 days
Heart Failure 2017 ACC/AHA/HFSA	ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have a reasonable expectation of meaningful survival for more than 1 year.	who have a reasonable expectation of meaningful survival for more than 1 year	{"Patient documented to have experienced a fall within asc":"C3534791","Documentation of patient survival and absence of stroke following cea":"C3710365","Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators (radiolog
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	patients who have LVEF of ?35%	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	a non-LBBB pattern with a QRS duration of ?150 ms	{"Planned chemotherapy regimen, including at a minimum: drug(s) prescribed, dose, and duration, documented prior to initiation of a new treatment regimen (ONC)":"C1971419","This code is for the onsite acute care treatment of a nursing facility reside
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	NYHA class III/ambulatory class IV symptoms on GDMT	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","Antibiotic regimen not prescribed within 10 days after onset of symptoms":"C4067437","HLA class I typing low resolution":"C3
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	patients who have LVEF of ?35%	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	LBBB with a QRS duration of 120–149 ms	{"Duration of general or neuraxial anesthesia 60 minutes or longer, as documented in the anesthesia record (CRIT) (Peri2)":"C2724383","Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration,
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	NYHA class II, III, or ambulatory class IV symptoms on GDMT	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","ALCOHOL AND\/OR DRUG SERVICES; MEDICAL\/SOMATIC (MEDICAL INTERVENTION IN AMBULATORY SETTING)":"C0919052","Ambulatory continu
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful in patients with AF and LVEF of ?35% on GDMT if a) the patient requires ventricular pacing or otherwise meets CRT criteria and b) atrioventricular nodal ablation or pharmacological rate control will allow near 100% ventricular pacing with CRT.	patients with AF and LVEF of ?35% on GDMT	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Left ventricul
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful in patients with AF and LVEF of ?35% on GDMT if a) the patient requires ventricular pacing or otherwise meets CRT criteria and b) atrioventricular nodal ablation or pharmacological rate control will allow near 100% ventricular pacing with CRT.	patient requires ventricular pacing or otherwise meets CRT criteria	{"Patient is not on a statin therapy":"C4316156","Temporary transcutaneous pacing":"C0199657","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Radiopharmaceutical, diagnostic, not otherwise classified":"C0497893","SUPPLY, NOT OTHERWISE S
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful in patients with AF and LVEF of ?35% on GDMT if a) the patient requires ventricular pacing or otherwise meets CRT criteria and b) atrioventricular nodal ablation or pharmacological rate control will allow near 100% ventricular pacing with CRT.	atrioventricular nodal ablation or pharmacological rate control will allow near 100% ventricular pacing with CRT	{"Catheter, extravascular tissue ablation, any modality (insertable)":"C3248389","Temporary transcutaneous pacing":"C0199657","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Application of low cost skin substitute graft to trunk, arms,
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients on GDMT who have LVEF of ?35% and are undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	patients on GDMT	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients on GDMT who have LVEF of ?35% and are undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	who have LVEF of ?35%	{"Patient documented to have experienced a fall within asc":"C3534791","Patient does not have respiratory insufficiency (ALS)":"C3534872","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Patient does not have verification and documentati
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients on GDMT who have LVEF of ?35% and are undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	{"Placement of temporary pacemaker leads":"C3513433","Placement of graft to first portion of aorta":"C3513584","Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key compon
Heart Failure 2017 ACC/AHA/HFSA	The usefulness of implantation of an ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk of nonsudden death as predicted by frequent hospitalizations, advanced frailty, or comorbidities such as systemic malignancy or severe renal dysfunction.	patients with a high risk of nonsudden death as predicted by frequent hospitalizations, advanced frailty, or comorbidities such as systemic malignancy or severe renal dysfunction.	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Advanced life support, level 2 (als 2)":"C0918298","Emergency department visit, moderately severe problem":"C351740
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	patients who have LVEF of ?35%	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	a non-LBBB pattern with a QRS duration of 120–149 ms	{"Planned chemotherapy regimen, including at a minimum: drug(s) prescribed, dose, and duration, documented prior to initiation of a new treatment regimen (ONC)":"C1971419","This code is for the onsite acute care treatment of a nursing facility reside
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	and NYHA class III/ambulatory class IV on GDMT	{"HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each":"C3248209","Antibody detection for HLA class II":"C3525863","HLA class II typing low resolution one locus":"C3516277","One class a finding":"C049
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	patients who have LVEF of ?35%	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	a non-LBBB pattern with a QRS duration of ?150 ms	{"Planned chemotherapy regimen, including at a minimum: drug(s) prescribed, dose, and duration, documented prior to initiation of a new treatment regimen (ONC)":"C1971419","This code is for the onsite acute care treatment of a nursing facility reside
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	NYHA class II symptoms on GDMT	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","Antibiotic regimen not prescribed within 10 days after onset of symptoms":"C4067437","HLA class I typing low resolution":"C3
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	patients who have LVEF of ?30%	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	ischemic etiology of HF	{"Ischemic stroke symptom onset of less than 3 hours prior to arrival (STR)":"C1964096","Asymptomatic carotid stenosis: No history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory (NMA-No Measure Associated)":"C3
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	sinus rhythm	{"Heart rhythm analysis, interpretation and report of 48-hour EKG":"C3516988","Insertion of probe into esophagus for recording and pacing upper or lower heart rhythm":"C3517065","Evaluation and insertion of catheters for recording, pacing, and treatm
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	LBBB with a QRS duration of ?150 ms	{"Duration of general or neuraxial anesthesia 60 minutes or longer, as documented in the anesthesia record (CRIT) (Peri2)":"C2724383","Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration,
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	NYHA class I symptoms on GDMT	{"Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Antibody detection for HLA class II":"C3525863","Antibiotic regimen not prescribed within 10 days after onset of symptoms":"C4067437","HLA class I typing low resolution":"C3
Heart Failure 2017 ACC/AHA/HFSA	CRT is NOT recommended for patients with NYHA class I or II symptoms and non-LBBB pattern with a QRS duration of <150 ms.	patients with NYHA class I or II symptoms	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Patien
Heart Failure 2017 ACC/AHA/HFSA	CRT is NOT recommended for patients with NYHA class I or II symptoms and non-LBBB pattern with a QRS duration of <150 ms.	non-LBBB pattern with a QRS duration of <150 ms	{"Planned chemotherapy regimen, including at a minimum: drug(s) prescribed, dose, and duration, documented prior to initiation of a new treatment regimen (ONC)":"C1971419","This code is for the onsite acute care treatment of a nursing facility reside
Heart Failure 2017 ACC/AHA/HFSA	CRT is NOT indicated for patients whose comorbidities and/or frailty limit survival with good functional capacity to <1 year.	patients whose comorbidities and/or frailty limit survival with good functional capacity to <1 year	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Documentation of patient survival and absence of stroke following cea":"C3710365"
Heart Failure 2017 ACC/AHA/HFSA	Fluid restriction (1.5–2 L/d) is reasonable in stage D, especially in patients with hyponatremia, to reduce congestive symptoms.	especially in patients with hyponatremia	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Fluid restriction (1.5–2 L/d) is reasonable in stage D, especially in patients with hyponatremia, to reduce congestive symptoms.	in stage D	{"Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional c
Heart Failure 2017 ACC/AHA/HFSA	Until definitive therapy (eg, coronary revascularization, MCS, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve endorgan performance.	Until definitive therapy (eg, coronary revascularization, MCS, heart transplantation)	{"Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 1-3":"C3865333","Patient is not on a statin therapy":"C4316156","Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"
Heart Failure 2017 ACC/AHA/HFSA	Until definitive therapy (eg, coronary revascularization, MCS, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve endorgan performance.	or resolution of the acute precipitating problem,	{"HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1\/3\/4\/5, and -DQB1":"C3248205","High resolution fractionation and measurement of lipoprotein with subclasses in blood":"C3525759","ALCOHOL AND\/OR DRUG SERVI
Heart Failure 2017 ACC/AHA/HFSA	Until definitive therapy (eg, coronary revascularization, MCS, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve endorgan performance.	patients with cardiogenic shock	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Anesthesia for electroconvulsive therapy":"C0198856","Patients prescribed opiates
Heart Failure 2017 ACC/AHA/HFSA	Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D Heart Failure refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation.	patients with stage D HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","1-stage":"C386
Heart Failure 2017 ACC/AHA/HFSA	Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D Heart Failure refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation.	refractory to GDMT and device therapy	{"Patient is not on a statin therapy":"C4316156","Flutter device":"C0994172","Speech therapy, in the home, per diem":"C0812852","Narrowing device, wheelchair":"C0498549","Insertion of radiation therapy devices in vagina for radiation therapy":"C35148
Heart Failure 2017 ACC/AHA/HFSA	Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D Heart Failure refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation.	who are eligible for and awaiting MCS or cardiac transplantation.	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Cord blood harvesting for transplantation, allogeneic":"C0919176","Clinician documented that patient was not an eli
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	hospitalized patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	presenting with documented severe systolic dysfunction	{"Level 1 outpatient visit for evaluation and management of established patient with minimal presenting problem, without history, physical examination, or medical decision making - typical time less than 5 minutes":"C3709166","A patient with severe s
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	who present with low blood pressure	{"Cord blood harvesting for transplantation, allogeneic":"C0919176","Chlamydia, gonorrhea and syphilis screening results documented (report when results are present for all of the 3 screenings)":"C3710332","Blood Patch, Epidural":"C0162649","Family\/
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance	{"Pulmonary perfusion imaging":"C3525539","Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)":"C0371631","Pulmonary ve
Heart Failure 2017 ACC/AHA/HFSA	Long-term, continuous intravenous inotropic support may be considered as palliative therapy for symptom control in select patients with stage D Heart Failure despite optimal GDMT and device therapy who are not eligible for either MCS or cardiac transplantation.	select patients with stage D HF despite optimal GDMT and device therapy	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient is not on a statin therapy":"C4316156","Patients prescribed opiates for l
Heart Failure 2017 ACC/AHA/HFSA	Long-term, continuous intravenous inotropic support may be considered as palliative therapy for symptom control in select patients with stage D Heart Failure despite optimal GDMT and device therapy who are not eligible for either MCS or cardiac transplantation.	who are not eligible for either MCS or cardiac transplantation.	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Cord blood harvesting for transplantation, allogeneic":"C0919176","Clinician documented that patient was not an eli
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	patient with HF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	in the absence of specific indications or for reasons other than palliative care	{"Documentation of patient survival and absence of stroke following cea":"C3710365","Patient is currently on a daily aspirin or other antiplatelet":"C4316160","Dilated macular or fundus exam performed, including documentation of the presence or absen
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	hospitalized patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	without documented severe systolic dysfunction,	{"Falls plan of care documented (GER)":"C1971418","Major depressive disorder, severe with psychotic features (MDD)":"C1737769","No record of hbv results documented":"C4542745","Most recent systolic blood pressure < 140 mmhg":"C2729230","MRI of bilate
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	low blood pressure	{"Cord blood harvesting for transplantation, allogeneic":"C0919176","Hemodialysis Unit Blood Pumps":"C0181177","Segmental gradient pressure pneumatic appliance, full leg":"C0498494","Blood Patch, Epidural":"C0162649","Basic metabolic panel":"C2237045
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	or impaired perfusion	{"Patient exhibits dysphagia, weight loss, or impaired nutrition (ALS)":"C3702523","Pulmonary perfusion imaging":"C3525539","Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or g
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	and evidence of significantly depressed cardiac output, with or without congestion	{"MRI of bilateral breasts without contrast":"C0993826","Transesophageal doppler measurement of cardiac output (including probe placement, image acquisition, and interpretation per course of treatment) for monitoring purposes":"C3534706","Measurement
Heart Failure 2017 ACC/AHA/HFSA	MCS is beneficial in carefully selected patients with stage D Heart FailurerEF in whom definitive management (eg, cardiac transplantation) or cardiac recovery is anticipated or planned.	carefully selected patients with stage D HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","1-stage":"C386
Heart Failure 2017 ACC/AHA/HFSA	MCS is beneficial in carefully selected patients with stage D Heart FailurerEF in whom definitive management (eg, cardiac transplantation) or cardiac recovery is anticipated or planned.	in whom definitive management (eg, cardiac transplantation) or cardiac recovery is anticipated or planned	{"Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 1-3":"C3865333","Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Radiation therapy management":"C01503
Heart Failure 2017 ACC/AHA/HFSA	Nondurable MCS, including the use of percutaneous and extracorporeal ventricular assist devices, is reasonable as a “bridge to recovery” or a “bridge to decision” for carefully selecteda Heart FailurerEF a H patients with acute, profound hemodynamic compromise.	carefully selected HFrEF patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Nondurable MCS, including the use of percutaneous and extracorporeal ventricular assist devices, is reasonable as a “bridge to recovery” or a “bridge to decision” for carefully selecteda Heart FailurerEF a H patients with acute, profound hemodynamic compromise.	with acute, profound hemodynamic compromise	{"Revision of transvenous intrahepatic portosystemic shunt(s) (TIPS) (includes venous access, hepatic and portal vein catheterization, portography with hemodynamic evaluation, intrahepatic tract recanulization\/dilatation, stent placement and all ass
Heart Failure 2017 ACC/AHA/HFSA	Durable MCS is reasonable to prolong survival for carefully selecteda a patients with stage D Heart FailurerEF.	carefully selected a patients with stage D HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","1-stage":"C386
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	carefully selected patients	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	with stage D HF	{"Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional c
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	GDMT	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	device management	{"Management of radiation therapy, 3D":"C3516052","DIABETIC MANAGEMENT PROGRAM, DIETITIAN VISIT":"C0812858","Case management, per month":"C1314622","Flutter device":"C0994172","Narrowing device, wheelchair":"C0498549","Radiation therapy management":"
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	surgical management	{"Management of radiation therapy, 3D":"C3516052","DIABETIC MANAGEMENT PROGRAM, DIETITIAN VISIT":"C0812858","Case management, per month":"C1314622","Radiation therapy management":"C0150318","Surgical Team":"C0520261","Surgical supply; miscellaneous":
Heart Failure 2017 ACC/AHA/HFSA	ACS precipitating acute Heart Failure decompensation should be promptly identified by ECG and serum biomarkers, including cardiac troponin testing, and treated optimally as appropriate to the overall condition and prognosis of the patient.	patient with ACS precipitating acute HF decompensation	{"Patient is not on a statin therapy":"C4316156","Patient lift, electric with seat or sling":"C0498482","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Complex chronic care management services, with the followin
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	during initial evaluation	{"Dmepos item, initial claim, purchase or first month rental":"C0497638","No documentation of signed an opioid treatment agreement at least once during opioid therapy":"C4067513","Patient is using hospice services any time during the measurement peri
Heart Failure 2017 ACC/AHA/HFSA	In patients with Heart FailurerEF experiencing a symptomatic exacerbation of Heart Failure requiring hospitalization during chronic maintenance treatment with GDMT, it is recommended that GDMT be continued in the absence of hemodynamic instability or contraindications.	In patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	In patients with Heart FailurerEF experiencing a symptomatic exacerbation of Heart Failure requiring hospitalization during chronic maintenance treatment with GDMT, it is recommended that GDMT be continued in the absence of hemodynamic instability or contraindications.	experiencing a symptomatic exacerbation of HF requiring hospitalization during chronic maintenance treatment with GDMT	{"Manipulation of spine requiring anesthesia, any region":"C0186069","Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis
Heart Failure 2017 ACC/AHA/HFSA	Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.	after optimization of volume status	{"CT scan of middle spine before and after contrast":"C3515792","Patient transfer to practice after initiation of chemotherapy":"C4316126","CT scan of cranial cavity before and after contrast":"C3515746","Corrugated tubing, disposable, used with larg
Heart Failure 2017 ACC/AHA/HFSA	Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.	successful discontinuation of intravenous diuretics	{"Ustekinumab, for intravenous injection, 1 mg":"C4542691","Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg":"C1971337","Radiopharmaceutical therapy, by intravenous administration":"C1504153","Injection, imm
Heart Failure 2017 ACC/AHA/HFSA	Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.	successful discontinuation of vasodilators	{"Excised tissue not evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion":"C3248608","Documentation of medical or patient reason(s) for not discussing treatment options; medical reasons: patient is not a candidate
Heart Failure 2017 ACC/AHA/HFSA	Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.	successful discontinuation of inotropic agents	{"Patient received combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and\/or intraoperatively":"C4542776","Application of chemical agents activated by ultraviolet light to
Heart Failure 2017 ACC/AHA/HFSA	Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.	only in stable patient	{"Footrest, upper hanger bracket, replacement only, each":"C0499203","Patient is not on a statin therapy":"C4316156","Drive belt for power wheelchair, replacement only":"C0499257","Chemotherapy administration by infusion technique only, per visit":"C
Heart Failure 2017 ACC/AHA/HFSA	Caution should be used when initiating the use of beta blockers in patients who have required inotropes during their hospital course.	patients who have required inotropes during their hospital course.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient documented to have experienced a fall within asc":"C3534791","Patients pr
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity.	Patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity.	admitted with evidence of significant fluid overload	{"Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of high complexit
Heart Failure 2017 ACC/AHA/HFSA	If patients are already receiving loop diuretic therapy, the initial intravenous dose should equal or exceed their chronic oral daily dose	patients are receiving loop diuretic therapy	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient receiving antiviral treatment for Hepatitis C (HEP-C)":"C1971487","Patien
Heart Failure 2017 ACC/AHA/HFSA	The effect of Heart Failure treatment should be monitored with careful measurement of fluid intake and output, vital signs, body weight that is determined at the same time each day, and clinical signs and symptoms of systemic perfusion and congestion. Daily serum electrolytes, urea nitrogen, and creatinine concentrations should be measured during the use of intravenous diuretics or active titration of Heart Failure medications.	patients with HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	When diuresis is inadequate to relieve symptoms, it is reasonable to intensify the diuretic regimen using either: a. Higher doses of intravenous loop diuretics (IIa-B), or b. Addition of a second (eg, thiazide) diuretic (IIa-B).	When diuresis is inadequate to relieve symptoms	{"Removal of brain tissue to relieve seizure activity":"C3515162","Neuropsychiatric symptoms assessed and results reviewed (DEM)":"C3248263","Chlamydia, gonorrhea and syphilis screening results documented (report when results are present for all of t
Heart Failure 2017 ACC/AHA/HFSA	Low-dose dopamine infusion may be considered in addition to loop diuretic therapy to improve diuresis and better preserve renal functio and renal blood flow.	improve diuresis and better preserve renal functio and renal blood flow	{"Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring)":"C0993920","Congo red, blood":"C0500231","Laser treatment of heart muscle to improve blo
Heart Failure 2017 ACC/AHA/HFSA	Ultrafiltration may be considered for patients with obvious volume overload to alleviate congestive symptoms and fluid weight.	patients with obvious volume overload	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Two patients s
Heart Failure 2017 ACC/AHA/HFSA	Ultrafiltration may be considered for patients with refractory congestion not responding to medical therapy.	patients with refractory congestion not responding to medical therapy.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patient is not on a statin therapy":"C4316156","Patients prescribed opiates for l
Heart Failure 2017 ACC/AHA/HFSA	If symptomatic hypotension is absent, intravenous nitroglycerin, nitroprusside, or nesiritide may be considered as an adjuvant to diuretic therapy for relief of dyspnea in patients admitted with acute decompensated Heart Failure.	symptomatic hypotension is absent	{"Fitting and provision of temporary contact lens for patient absent a natural lens":"C3516875","Documentation of medical reason(s) for ordering an advanced brain imaging study (i.e., patient has an abnormal neurological examination; patient has the
Heart Failure 2017 ACC/AHA/HFSA	If symptomatic hypotension is absent, intravenous nitroglycerin, nitroprusside, or nesiritide may be considered as an adjuvant to diuretic therapy for relief of dyspnea in patients admitted with acute decompensated Heart Failure.	patients admitted with acute decompensated HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","ALCOHOL AND\/O
Heart Failure 2017 ACC/AHA/HFSA	A patient admitted to the hospital with decompensated Heart Failure should receive venous thromboembolism prophylaxis with an anticoagulant medication if the risk–benefit ratio is favorable.	A patient admitted to the hospital with decompensated HF	{"Hospital mandated on call service; in-hospital, each hour":"C1144774","Patient is not on a statin therapy":"C4316156","Patient lift, electric with seat or sling":"C0498482","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":
Heart Failure 2017 ACC/AHA/HFSA	In patients hospitalized with volume overload, including Heart Failure, who have persistent severe hyponatremia and are at risk for or having active cognitive symptoms despite water restriction and maximization of GDMT, vasopressin antagonists may be considered in the short term to improve serum sodium concentration in hypervolemic, hyponatremic states with either a V2 receptor–selective or a nonselective vasopressin antagonist.	patients hospitalized with volume overload, including HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Etonogestrel (contraceptive) implant system, including implant and supplies":"C17
Heart Failure 2017 ACC/AHA/HFSA	In patients hospitalized with volume overload, including Heart Failure, who have persistent severe hyponatremia and are at risk for or having active cognitive symptoms despite water restriction and maximization of GDMT, vasopressin antagonists may be considered in the short term to improve serum sodium concentration in hypervolemic, hyponatremic states with either a V2 receptor–selective or a nonselective vasopressin antagonist.	who have persistent severe hyponatremia	{"Patient documented to have experienced a fall within asc":"C3534791","Major depressive disorder, severe with psychotic features (MDD)":"C1737769","Documentation of permanent or persistent or paroxysmal atrial fibrillation (STR)":"C1964094","Patient
Heart Failure 2017 ACC/AHA/HFSA	In patients hospitalized with volume overload, including Heart Failure, who have persistent severe hyponatremia and are at risk for or having active cognitive symptoms despite water restriction and maximization of GDMT, vasopressin antagonists may be considered in the short term to improve serum sodium concentration in hypervolemic, hyponatremic states with either a V2 receptor–selective or a nonselective vasopressin antagonist.	are at risk for or having active cognitive symptoms despite water restriction and maximization of GDMT	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Health-related quality of life not assessed with tool for documented reason(s) (e.g., patient has a cognitive or ne
Heart Failure 2017 ACC/AHA/HFSA	The use of performance improvement systems and/or evidence-based systems of care is recommended in the hospital and early postdischarge outpatient setting to identify appropriate Heart Failure patients for GDMT, provide clinicians with useful reminders to advance GDMT, and assess the clinical response.	identify appropriate HF patients for GDMT	{"Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given":"C3710404","Four patients se
Heart Failure 2017 ACC/AHA/HFSA	The use of performance improvement systems and/or evidence-based systems of care is recommended in the hospital and early postdischarge outpatient setting to identify appropriate Heart Failure patients for GDMT, provide clinicians with useful reminders to advance GDMT, and assess the clinical response.	provide clinicians with useful reminders to advance GDMT	{"Advance Care Planning":"C0600371","Advance care planning including the explanation and discussion of advance directives such as standard forms (with completion of such forms, when performed), by the physician or other qualified health care professi
Heart Failure 2017 ACC/AHA/HFSA	The use of performance improvement systems and/or evidence-based systems of care is recommended in the hospital and early postdischarge outpatient setting to identify appropriate Heart Failure patients for GDMT, provide clinicians with useful reminders to advance GDMT, and assess the clinical response.	assess the clinical response	{"Investigational clinical service provided in a clinical research study that is in an approved clinical research study":"C1971589","All lower extremity prosthesis, multi-axial ankle, dynamic response foot, one piece system":"C0499983","Tuberculosis
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	Throughout the hospitalization as appropriate,	{"Partial hospitalization services, less than 24 hours, per diem":"C1314502","Control oropharyngeal hemorrhage, primary or secondary (eg, post-tonsillectomy); complicated, requiring hospitalization":"C0371957","Interactive group psychotherapy, in a p
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	before hospital discharge,	{"Hospital mandated on call service; in-hospital, each hour":"C1144774","CT scan of middle spine before and after contrast":"C3515792","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","CT scan of cranial cavity be
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	at the first postdischarge visit	{"Placement of graft to first portion of aorta":"C3513584","Acupuncture 1 or more needles, first 15 minutes":"C3704124","Dmepos item, initial claim, purchase or first month rental":"C0497638","Nutritional counseling, dietitian visit":"C0812859","DIAB
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	in subsequent follow-up visits	{"Dialysis services (2-3 physician visits per month), patient 12-19 years of age":"C3703997","Total number of emergency department visits and inpatient hospitalizations less than two in the past 12 months":"C4067472","Dialysis services (4 or more phy
Heart Failure 2017 ACC/AHA/HFSA	Multidisciplinary Heart Failure disease-management programs are recommended for patients at high risk for hospital readmission, to facilitate the implementation of GDMT, to address different barriers to behavioral change, and to reduce the risk of subsequent rehospitalization for Heart Failure.	for patients at high risk for hospital readmission	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Hospital mandated on call service; in-hospital, each hour":"C1144774","Patients p
Heart Failure 2017 ACC/AHA/HFSA	Scheduling an early follow-up visit (within 7–14 days) and early telephone follow-up (within 3 days) of hospital discharge is reasonable.	(within 3 days) of hospital discharge	{"Hospital mandated on call service; in-hospital, each hour":"C1144774","ALCOHOL AND\/OR DRUG SERVICES; ACUTE DETOXIFICATION (HOSPITAL INPATIENT)":"C0919045","Initial inpatient pediatric critical care, per day, for the evaluation and management of a
Heart Failure 2017 ACC/AHA/HFSA	Use of clinical risk-prediction tools and/or biomarkers to identify patients at higher risk for postdischarge clinical events is reasonable.	identify patients at higher risk for postdischarge clinical events	{"Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given":"C3710404","Four patients se
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II and III Heart Failure and iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL.	patients with NYHA class II and III HF and iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL if transferrin saturation is <20%)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd o
Heart Failure 2017 ACC/AHA/HFSA	In patients with Heart Failure and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality.	patients with HF and anemia	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd o
Heart Failure 2017 ACC/AHA/HFSA	In patients at increased risk, stage A Heart Failure, the optimal blood pressure in those with hypertension should be <130/80 mm Hg.	In patients at increased risk, stage A HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Gene analysis
Heart Failure 2017 ACC/AHA/HFSA	In patients at increased risk, stage A Heart Failure, the optimal blood pressure in those with hypertension should be <130/80 mm Hg.	in those with hypertension	{"Craniectomy or craniotomy, decompressive, with or without duraplasty, for treatment of intracranial hypertension, without evacuation of associated intraparenchymal hematoma; with lobectomy":"C1144683","Patient not screened for uterine malignancy, o
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurerEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg.	Patients with HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurerEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg.	and hypertension	{"Craniectomy or craniotomy, decompressive, with or without duraplasty, for treatment of intracranial hypertension, without evacuation of associated intraparenchymal hematoma; with lobectomy":"C1144683","Craniectomy or craniotomy, decompressive, with
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurepEF and persistent hypertension after management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg	Patients with HFpEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurepEF and persistent hypertension after management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg	persistent hypertension after management of volume overload	{"Management of radiation therapy, 3D":"C3516052","Documentation of permanent or persistent or paroxysmal atrial fibrillation (STR)":"C1964094","CT scan of middle spine before and after contrast":"C3515792","DIABETIC MANAGEMENT PROGRAM, DIETITIAN VIS
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart Failure and suspicion of sleep disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable	In patients with NYHA class II–IV HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Antibody detec
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart Failure and suspicion of sleep disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable	and suspicion of sleep disordered breathing	{"Upper gastrointestinal endoscopy report indicates suspicion of Barrett's esophagus (GERD)":"C1964126","Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only":"C4067652","Pediatric home monitoring of breathing
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart Failure and suspicion of sleep disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable	or excessive daytime sleepiness,	{"Documentation of reason(s) for not documenting an assessment of sleep symptoms (e.g., patient didn't have initial daytime sleepiness, patient visited between initial testing and initiation of therapy)":"C3248576","Removal of excessive skin and tiss
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	In patients with cardiovascular disease	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Other cardiova
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	obstructive sleep apnea	{"Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only":"C4067652","Documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	In patients with NYHA class II–IV HFrEF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Antibody detec
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	central sleep apnea	{"Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only":"C4067652","Insertion of central venous catheter and implanted device for infusion beneath the skin":"C3703279","Insertion of central venous catheters for
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	patients (HFpEF and HFrEF) on GDMT	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	with angina	{"Severity of angina assessed by level of activity (CAD)":"C3248256","Angina present (CAD)":"C3248257","NO RESULTS":"NONE","Angina absent (CAD)":"C3248525"}
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease	{"Left ventricular ejection fraction (lvef) < 40%":"C3248440","A patient with severe systemic disease that is a constant threat to life":"C0973440","Ultrasound of eye disease, growth, or structure":"C3515986","Right ventricular resection for infundib
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft to improve survival is reasonable in patients with mild to moderate LV systolic dysfunction (EF 35%–50%) and significant (?70% diameter stenosis) multivessel CAD or proximal left anterior descending (LAD) coronary artery stenosis when viable myocardium is present in the region of intended revascularization. (IIa-B)	patients with mild to moderate LV systolic dysfunction (EF 35%–50%)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Summary of CPT Codes That Include Moderate (Conscious) Sedation":"C4291902","Pati
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft to improve survival is reasonable in patients with mild to moderate LV systolic dysfunction (EF 35%–50%) and significant (?70% diameter stenosis) multivessel CAD or proximal left anterior descending (LAD) coronary artery stenosis when viable myocardium is present in the region of intended revascularization. (IIa-B)	and significant (?70% diameter stenosis) multivessel coronary artery disease	{"Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of high complexit
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft to improve survival is reasonable in patients with mild to moderate LV systolic dysfunction (EF 35%–50%) and significant (?70% diameter stenosis) multivessel CAD or proximal left anterior descending (LAD) coronary artery stenosis when viable myocardium is present in the region of intended revascularization. (IIa-B)	or proximal left anterior descending coronary artery stenosis when viable myocardium is present in the region of intended revascularization.	{"Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion":"C4542803","Left ventricular ejection fraction (lvef) < 40%":"C3248440","Bypass of diseased or blocked artery (c
Heart Failure 2017 ACC/AHA/HFSA	CABG or medical therapy is reasonable to improve morbidity and cardiovascular mortality for patients with severe LV dysfunction (EF <35%), Heart Failure, and significant CAD.	patients with severe LV dysfunction (EF <35%)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Major depressive disorder, severe with psychotic features (MDD)":"C1737769","Pati
Heart Failure 2017 ACC/AHA/HFSA	CABG or medical therapy is reasonable to improve morbidity and cardiovascular mortality for patients with severe LV dysfunction (EF <35%), Heart Failure, and significant CAD.	heart failure	{"Repair of wound to heart on heart-lung machine":"C3513471","External shock to heart to regulate heart beat":"C3516959","Anesthesia for heart\/lung transplant":"C0198934","Transplantation of donor heart":"C3513602","Clinician documented that patient
Heart Failure 2017 ACC/AHA/HFSA	CABG or medical therapy is reasonable to improve morbidity and cardiovascular mortality for patients with severe LV dysfunction (EF <35%), Heart Failure, and significant CAD.	significant coronary artery disease	{"Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of high complexit
Heart Failure 2017 ACC/AHA/HFSA	Surgical aortic valve replacement is reasonable for patients with critical aortic stenosis and a predicted surgical mortality of <10%. (IIa-B)	patients with critical aortic stenosis	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Two patients s
Heart Failure 2017 ACC/AHA/HFSA	Surgical aortic valve replacement is reasonable for patients with critical aortic stenosis and a predicted surgical mortality of <10%. (IIa-B)	and a predicted surgical mortality of <10%.	{"Surgical stockings thigh length, each":"C0497862","Prostate cancer mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-s
Heart Failure 2017 ACC/AHA/HFSA	Transcatheter aortic valve replacement after careful candidate consideration is reasonable for patients with critical aortic stenosis who are deemed inoperable. (IIa-B)	patients with critical aortic stenosis	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Two patients s
Heart Failure 2017 ACC/AHA/HFSA	Transcatheter aortic valve replacement after careful candidate consideration is reasonable for patients with critical aortic stenosis who are deemed inoperable. (IIa-B)	who are deemed inoperable	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	CABG may be considered with the intent of improving survival in patients with ischemic heart disease with severe LV systolic dysfunction (EF <35%) and operable coronary anatomy whether or not viable myocardium is present. (IIb-B)	patients with ischemic heart disease with severe LV systolic dysfunction (EF <35%)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Anesthesia for
Heart Failure 2017 ACC/AHA/HFSA	CABG may be considered with the intent of improving survival in patients with ischemic heart disease with severe LV systolic dysfunction (EF <35%) and operable coronary anatomy whether or not viable myocardium is present. (IIb-B)	and operable coronary anatomy whether or not viable myocardium is present.	{"Chlamydia, gonorrhea and syphilis screening results documented (report when results are present for all of the 3 screenings)":"C3710332","Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation
Heart Failure 2017 ACC/AHA/HFSA	Transcatheter mitral valve repair or mitral valve surgery for functional mitral insufficiency is of uncertain benefit and should only be considered after careful candidate selection and with a background of GDMT.	after careful candidate selection	{"Clinician documented that patient was not an eligible candidate for footwear evaluation measure":"C1971258","CT scan of middle spine before and after contrast":"C3515792","Clinician documented that patient was not an eligible candidate for angioten
Heart Failure 2017 ACC/AHA/HFSA	Transcatheter mitral valve repair or mitral valve surgery for functional mitral insufficiency is of uncertain benefit and should only be considered after careful candidate selection and with a background of GDMT.	and with a background of GDMT.	{"NO RESULTS":"NONE"}
Heart Failure 2017 ACC/AHA/HFSA	Surgical reverse remodeling or LV aneurysmectomy may be considered in carefully selected patients with Heart FailurerEF for specific indications including intractable Heart Failure and ventricular arrhythmias.	carefully selected patients with HFrEF for specific indications including intractable HF and ventricular arrhythmias.	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Left ventricul
Heart Failure 2017 ACC/AHA/HFSA	Effective systems of care coordination with special attention to care transitions should be deployed for every patient with chronic Heart Failure that facilitate and ensure effective care that is designed to achieve GDMT and prevent hospitalization.	every patient with chronic HF that facilitate and ensure effective care that is designed to achieve GDMT and prevent hospitalization	{"Patient did not achieve an improvement in visual acuity, from their preoperative level, within 90 days of surgery, reason not given":"C4067468","Patient is not on a statin therapy":"C4316156","Services performed by a qualified physical therapist, i
Heart Failure 2017 ACC/AHA/HFSA	Every patient with Heart Failure should have a clear, detailed, and evidencebased plan of care that ensures the achievement of GDMT goals, effective management of comorbid conditions, timely follow-up with the healthcare team, appropriate dietary and physical activities, and compliance with secondary prevention guidelines for cardiovascular disease. This plan of care should be updated regularly and made readily available to all members of each patient’s healthcare team. (I-C)	patient with HF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	Palliative and supportive care is effective for patients with symptomatic advanced Heart Failure to improve quality of life. (I-B)	patients with symptomatic advanced HF	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Advanced life support, level 2 (als 2)":"C0918298","Patients prescribed opiates f
Heart Failure 2017 ACC/AHA/HFSA	Performance measures based on professionally developed clinical practice guidelines should be used with the goal of improving quality of care for Heart Failure.	patient with HF	{"Patient is not on a statin therapy":"C4316156","Patient not prescribed or dispensed antibiotic":"C3248453","Patient lift, electric with seat or sling":"C0498482","Patient care survey was not completed by patient":"C3248429","Patient survey results
Heart Failure 2017 ACC/AHA/HFSA	Participation in quality improvement programs and patient registries based on nationally endorsed, clinical practice guideline–based quality and performance measures can be beneficial in improving quality of Heart Failure care.	in improving quality of HF care.	{"Health-related quality of life not assessed with tool for documented reason(s) (e.g., patient has a cognitive or neuropsychiatric impairment that impairs his\/her ability to complete the hrqol survey, patient has the inability to read and\/or write
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest noninvasive sampling with semiquantitative cultures to diagnose VAP, rather than invasive sampling with quantitative cultures and rather than noninvasive sampling with quantitative cultures	diagnosing VAP	{"Pathology report diagnosing cutaneous basal cell carcinoma or squamous cell carcinoma (to include in situ disease) was not sent from the pathologist\/dermatopathologist to the biopsying clinician for review within 7 days from the time when the tiss
Hospital-Acquired and VentilatorAssociated Pneumonia	Noninvasive sampling with semiquantitative cultures is the preferred methodology to diagnose VAP (see section I); however, the panel recognizes that invasive quantitative cultures will occasionally be performed by some clinicians. For patients with suspected VAP whose invasive quantitative culture results are below the diagnostic threshold for VAP, we suggest that antibiotics be withheld rather than continued	patients with suspected VAP whose invasive quantitative culture results are below the diagnostic threshold	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Quinidine measurement":"C0337453","Radiopharmaceutical, diagnostic, not otherwise classified":"C0497893","Two patie
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest that patients with suspected HAP (non-VAP) be treated according to the results of microbiologic studies performed on respiratory samples obtained noninvasively, rather than being treated empirically	patients with suspected HAP (non-VAP)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with suspected HAP/VAP, we recommend using clinical criteria alone, rather than using serum PCT plus clinical criteria, to decide whether or not to initiate antibiotic therapy	For patients with suspected HAP/VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with suspected HAP/VAP, we recommend using clinical criteria alone, rather than using bronchoalveolar lavage fluid (BALF) sTREM-1 plus clinical criteria, to decide whether or not to initiate antibiotic therapy	patients with suspected HAP/VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with suspected HAP/VAP, we recommend using clinical criteria alone rather than using CRP plus clinical criteria, to decide whether or not to initiate antibiotic therapy	patients with suspected HAP/VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with suspected HAP/VAP, we suggest using clinical criteria alone, rather than using CPIS plus clinical criteria, to decide whether or not to initiate antibiotic therapy	patients with suspected HAP/VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with VAT, we suggest not providing antibiotic therapy	patients with VAT	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with suspected VAP, we recommend including coverage for S. aureus, Pseudomonas aeruginosa, and other gram-negative bacilli in all empiric regimens	patients with suspected VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest including an agent active against MRSA for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients being treated in units where >10%–20% of S. aureus isolates are methicillin resistant, and patients in units where the prevalence of MRSA is not known	patients with a risk factor for antimicrobial resistance (Table 2)	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Two patients s
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest including an agent active against MRSA for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients being treated in units where >10%–20% of S. aureus isolates are methicillin resistant, and patients in units where the prevalence of MRSA is not known	patients being treated in units where >10%–20% of S. aureus isolates are methicillin resistant	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest including an agent active against MRSA for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients being treated in units where >10%–20% of S. aureus isolates are methicillin resistant, and patients in units where the prevalence of MRSA is not known	patients in units where the prevalence of MRSA is not known	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Esophagogastro
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest including an agent active against methicillinsensitive S. aureus (MSSA) (and not MRSA) for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance, who are being treated in ICUs where <10%–20% of S. aureus isolates are methicillin resistant (weak recommendation, very low-quality evidence).	patients without risk factors for antimicrobial resistance, who are being treated in ICUs where <10%–20% of S. aureus isolates are methicillin resistant	{"PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","MRI of bilateral breasts without contrast":"C0993826","Two patients served":"C1314210","Beta-blocker therapy prescr
Hospital-Acquired and VentilatorAssociated Pneumonia	If empiric coverage for MRSA is indicated, we recommend either vancomycin or linezolid	empiric coverage for MRSA is indicated,	{"Endovascular repair of pseudoaneurysm of descending thoracic aorta with initial endoprosthesis, without coverage of left subclavian artery origin":"C3868925","Radiologic supervision and interpretation for endovascular repair of descending thoracic
Hospital-Acquired and VentilatorAssociated Pneumonia	When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem (weak recommendation, very low-quality evidence). Oxacillin, nafcillin, or cefazolin are preferred agents for treatment of proven MSSA, but are not necessary for the empiric treatment of VAP if one of the above agents is used.	When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated	{"Endovascular repair of pseudoaneurysm of descending thoracic aorta with initial endoprosthesis, without coverage of left subclavian artery origin":"C3868925","Rental (use the 'rr' modifier when dme is to be rented)":"C0497684","Transperineal implan
Hospital-Acquired and VentilatorAssociated Pneumonia	Oxacillin, nafcillin, or cefazolin are preferred agents for treatment of proven MSSA, but are not necessary for the empiric treatment of VAP if one of the above agents is used	treating proven MSSA	{"Documentation of reason(s) sentinel lymph node biopsy not performed (e.g., reasons could include but not limited to; non-invasive cancer, incidental discovery of breast cancer on prophylactic mastectomy, incidental discovery of breast cancer on red
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing 2 antipseudomonal antibiotics from different classes for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy, and patients in an ICU where local antimicrobial susceptibility rates are not available	for the empiric treatment of suspected VAP	{"Anesthesia for electroconvulsive therapy":"C0198856","Examination of genital and anal region of child using an endoscope, suspected trauma":"C3704131","Treatment planning and care coordination management for cancer, initial treatment":"C3534660","A
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing 2 antipseudomonal antibiotics from different classes for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy, and patients in an ICU where local antimicrobial susceptibility rates are not available	a risk factor for antimicrobial resistance (Table 2)	{"Dynamic knee, extension\/flexion device with active resistance control":"C1617828","At least two orders for the same high-risk medication":"C4542717","Patients not assessed for risk of bone loss, reason not given":"C3248597","Documentation of order
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing 2 antipseudomonal antibiotics from different classes for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy, and patients in an ICU where local antimicrobial susceptibility rates are not available	patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Two patients s
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing 2 antipseudomonal antibiotics from different classes for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy, and patients in an ICU where local antimicrobial susceptibility rates are not available	patients in an ICU where local antimicrobial susceptibility rates are not available	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Continuous infusions of local anesthetic for pain control and abdominal wall anal
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing one antibiotic active against P. aeruginosa for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance who are being treated in ICUs where ?10% of gram-negative isolates are resistant to the agent being considered for monotherapy	suspected VAP	{"Examination of genital and anal region of child using an endoscope, suspected trauma":"C3704131","Anogenital examination, magnified, in childhood for suspected trauma, including image recording when performed":"C3702189","Genetic testing, sodium ch
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing one antibiotic active against P. aeruginosa for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance who are being treated in ICUs where ?10% of gram-negative isolates are resistant to the agent being considered for monotherapy	patients without risk factors for antimicrobial resistance	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","MRI of bilater
Hospital-Acquired and VentilatorAssociated Pneumonia	We suggest prescribing one antibiotic active against P. aeruginosa for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance who are being treated in ICUs where ?10% of gram-negative isolates are resistant to the agent being considered for monotherapy	patients who are being treated in ICUs where ?10% of gram-negative isolates are resistant to the agent being considered for monotherapy	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with suspected VAP, we suggest avoiding aminoglycosides if alternative agents with adequate gram-negative activity are available	patients with suspected VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with suspected VAP, we suggest avoiding aminoglycosides if alternative agents with adequate gram-negative activity are available	alternative agents with adequate gram-negative activity are available	{"Removal of brain tissue to relieve seizure activity":"C3515162","Application of chemical agents activated by ultraviolet light to skin":"C3517288","Evaluation for prescription for speech-generating augmentative and alternative communication device,
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with suspected VAP, we suggest avoiding colistin if alternative agents with adequate gram-negative activity are available	In patients with suspected VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Examination of genital and anal region of child using an endoscope, suspected tra
Hospital-Acquired and VentilatorAssociated Pneumonia	In patients with suspected VAP, we suggest avoiding colistin if alternative agents with adequate gram-negative activity are available	alternative agents with adequate gram-negative activity are available	{"Removal of brain tissue to relieve seizure activity":"C3515162","Application of chemical agents activated by ultraviolet light to skin":"C3517288","Evaluation for prescription for speech-generating augmentative and alternative communication device,
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients being treated empirically for HAP, we recommend prescribing an antibiotic with activity against S. aureus	patients being treated empirically for HAP,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an antibiotic with activity against MRSA	patients with HAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an antibiotic with activity against MRSA	who are being treated empirically	{"Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Temporary replacement for patient owned equipment being repaired, any type":"C0812754","Patient has been treated with an oral systemic or biologi
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an antibiotic with activity against MRSA	a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant,	{"Unplanned hospital readmission within 30 days of principal procedure":"C3710411","Pneumococcal screening performed and documentation of vaccination received prior to discharge":"C3710383","At least two orders for the same high-risk medication":"C45
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an antibiotic with activity against MRSA	the prevalence of MRSA is not known	{"Mammogram assessment category of \"known biopsy proven malignancy,\" documented (RAD)":"C2366777","APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants":"C3511543","Gene
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an antibiotic with activity against MRSA	who are at high risk for mortality	{"One high-risk medication not ordered":"C3871285","Prostate cancer mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-sp
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who require empiric coverage for MRSA, we recommend vancomycin or linezolid rather than an alternative antibiotic	patients with HAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who require empiric coverage for MRSA, we recommend vancomycin or linezolid rather than an alternative antibiotic	who require empiric coverage for MRSA,	{"Endovascular repair of pseudoaneurysm of descending thoracic aorta with initial endoprosthesis, without coverage of left subclavian artery origin":"C3868925","Manipulation of temporomandibular joint(s) (TMJ), therapeutic, requiring an anesthesia se
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have no risk factors for MRSA infection and are not at high risk of mortality, we suggest prescribing an antibiotic with activity against MSSA. When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	patients with HAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have no risk factors for MRSA infection and are not at high risk of mortality, we suggest prescribing an antibiotic with activity against MSSA. When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	who are being treated empirically	{"Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Temporary replacement for patient owned equipment being repaired, any type":"C0812754","Patient has been treated with an oral systemic or biologi
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have no risk factors for MRSA infection and are not at high risk of mortality, we suggest prescribing an antibiotic with activity against MSSA. When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	have no risk factors for MRSA infection	{"Patient documented to have experienced a fall within asc":"C3534791","Irrigation and drainage of knee joint for infection using an endoscope":"C3513157","Prenatal care, at risk enhanced service; care coordination":"C0993932","Patient does not have
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have no risk factors for MRSA infection and are not at high risk of mortality, we suggest prescribing an antibiotic with activity against MSSA. When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	are not at high risk of mortality	{"One high-risk medication not ordered":"C3871285","Prostate cancer mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-sp
Hospital-Acquired and VentilatorAssociated Pneumonia	When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	empiric treatment that includes coverage for MSSA	{"Anesthesia for electroconvulsive therapy":"C0198856","Endovascular repair of pseudoaneurysm of descending thoracic aorta with initial endoprosthesis, without coverage of left subclavian artery origin":"C3868925","Alcohol and\/or other drug treatmen
Hospital-Acquired and VentilatorAssociated Pneumonia	When empiric treatment that includes coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. Oxacillin, nafcillin, or cefazolin are preferred for the treatment of proven MSSA, but are not necessary for empiric coverage of HAP if one of the above agents is used	not MRSA	{"Detection test for Staphylococcus aureus, methicillin resistant (MRSA bacteria)":"C3516604"}
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically, we recommend prescribing antibiotics with activity against P. aeruginosa and other gram-negative bacilli	For patients with HAP who are being treated empirically	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have factors increasing the likelihood for Pseudomonas or other gram-negative infection (ie, prior intravenous antibiotic use within 90 days; also see Remarks) or a high risk for mortality, we suggest prescribing antibiotics from 2 different classes with activity against P. aeruginosa	For patients with HAP who are being treated empirically	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have factors increasing the likelihood for Pseudomonas or other gram-negative infection (ie, prior intravenous antibiotic use within 90 days; also see Remarks) or a high risk for mortality, we suggest prescribing antibiotics from 2 different classes with activity against P. aeruginosa	have factors increasing the likelihood for Pseudomonas or other gram-negative infection	{"Patient documented to have experienced a fall within asc":"C3534791","Patient is currently on a daily aspirin or other antiplatelet":"C4316160","Irrigation and drainage of knee joint for infection using an endoscope":"C3513157","Alcohol and\/or oth
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically and have factors increasing the likelihood for Pseudomonas or other gram-negative infection (ie, prior intravenous antibiotic use within 90 days; also see Remarks) or a high risk for mortality, we suggest prescribing antibiotics from 2 different classes with activity against P. aeruginosa	a high risk for mortality	{"One high-risk medication not ordered":"C3871285","Prostate cancer mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-sp
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP who are being treated empirically, we recommend not using an aminoglycoside as the sole antipseudomonal agent	patients with HAP who are being treated empirically	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patient not tr
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP, we suggest that antibiotic dosing be determined using PK/PD data, rather than the manufacturer’s prescribing information	For patients with HAP/VAP	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with VAP due to gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins (colistin or polymyxin B), we suggest both inhaled and systemic antibiotics, rather than systemic antibiotics alone	patients with VAP due to gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins (colistin or polymyxin B),	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Footrest, upper hanger bracket, replacement only, each":"C0499203","Patients pres
Hospital-Acquired and VentilatorAssociated Pneumonia	We recommend that MRSA HAP/VAP be treated with either vancomycin or linezolid rather than other antibiotics or antibiotic combinations	MRSA HAP/VAP	{"Detection test for Staphylococcus aureus, methicillin resistant (MRSA bacteria)":"C3516604","NO RESULTS":"NONE"}
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa, we recommend that the choice of an antibiotic for definitive (not empiric) therapy be based upon the results of antimicrobial susceptibility testing	patients with HAP/VAP due to P. aeruginosa	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa, we recommend against aminoglycoside monotherapy (strong recommendation, very low-quality evidence).	For patients with HAP/VAP due to P. aeruginosa,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy	For patients with HAP/VAP due to P. aeruginosa,	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy	who are not in septic shock	{"Anesthesia for electroconvulsive therapy":"C0198856","External shock to heart to regulate heart beat":"C3516959","Global fee for extracorporeal shock wave lithotripsy treatment of kidney stone(s)":"C0994083","Extracorporeal shock wave involving mus
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy	at a high risk for death	{"Prenatal care, at risk enhanced service; care coordination":"C0993932","Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the deat
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy	for whom the results of antibiotic susceptibility testing are known,	{"Patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given":"C4067505","Chest X-ray results documented and reviewed (CAP)":"C1742717","Antibiotic regimen not prescribed within 10 days after onset of symptoms":"C406743
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who remain in septic shock or at a high risk for death when the results of antibiotic susceptibility testing are known, we suggest combination therapy using 2 antibiotics to which the isolate is susceptible rather than monotherapy	For patients with HAP/VAP due to P. aeruginosa	{"Four patients served":"C1314212","PATIENT IS NOT ELIGIBLE FOR THE REFERRAL FOR OTOLOGIC EVALUATION FOR PATIENTS WITH A HISTORY OF ACTIVE DRAINAGE MEASURE":"C2729203","Patients prescribed opiates for longer than six weeks":"C4067506","Patients witho
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who remain in septic shock or at a high risk for death when the results of antibiotic susceptibility testing are known, we suggest combination therapy using 2 antibiotics to which the isolate is susceptible rather than monotherapy	who remain in septic shock	{"Anesthesia for electroconvulsive therapy":"C0198856","External shock to heart to regulate heart beat":"C3516959","Global fee for extracorporeal shock wave lithotripsy treatment of kidney stone(s)":"C0994083","Extracorporeal shock wave involving mus
Hospital-Acquired and VentilatorAssociated Pneumonia	For patients with HAP/VAP due to P. aeruginosa who remain in septic shock or at a high risk for death when the results of antibiotic susceptibility testing are known, we suggest combination therapy using 2 antibiotics to which the isolate is susceptible rather than monotherapy	or at a high risk for death when the results of antibiotic susceptibility testing are known,